"We recognized that people's daily lives are busier than ever, and we knew we needed to meet people where they are facing the realities of real life," said Tonya Villafana, vice president of medical and scientific affairs at AstraZeneca.
Moderna's new mRNA-based flu vaccine, mRNA-1010, demonstrated a 27 percent higher efficacy rate in preventing influenza infections compared to the standard flu shot in a trial with nearly 41,000 participants aged 50 and older.